U.S. Markets closed

Wall Street Transcript Interview with Harold R. Wolcott, the Director and President of BSD Medical Corporation (BSDM)

67 WALL STREET, New York - August 2, 2013 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Cardiac - Health Care - Affordable Care Act - Continued Pricing Pressure - Aging U.S. Population

Companies include: BSD Medical Corp. (BSDM) and many more.

In the following excerpt from the Medical Devices Report, the Director and President of BSD Medical Corporation (BSDM) discusses company strategy and the outlook for this vital industry:

TWST: What is BSD Medical?

Mr. Wolcott: BSD Medical was founded in 1978 and is listed on Nasdaq under BSDM. We have pioneered medical device systems for the treatment of cancer, specifically by utilizing heat therapy. We have two segments to our business. The first is hyperthermia, which is a treatment modality that heats cancer to approximately 43 degrees centigrade. It causes changes in the cell physiology and dramatically increases the effectiveness of radiation and chemotherapy.

The second key modality we have is in the area of thermal ablation. We use microwave energy in both of our technologies; however, with our ablation therapy it is at a much higher temperature, 100 degrees centigrade or more. Our microwave ablation therapy, MicroThermX, has received 510(k) clearance from the FDA. MicroThermX is a standalone treatment, which uses microwave energy to destroy cancerous tissue. BSD Medical is fundamentally focused on thermal energy for oncology, because heat does amazing things for the treatment of cancer.

TWST: What are some of the advantages of hyperthermia and ablation treatment, and how much physician training is required?

Mr. Wolcott: Let us start with ablation. Ablation is a standalone treatment. A vast majority of the time it begins with a simple skin puncture. Utilizing imaging, the physician punctures the tumor with a microwave-emitting antenna. Over a 10 to 15 minute period, the microwave energy destroys the tumor. After withdrawing the antenna you can simply put a Band-Aid on the patient, and they go home the same day. This is radically different than many other more invasive surgical procedures for cancer that have been in use for decades.

BSD's hyperthermia treatment is also easy to use and less invasive. Hyperthermia treats superficial or deep-tissue tumors by elevating the temperature of the tumor, increasing blood perfusion and the oxygen in the tumor. Radiation particularly works in the presence of oxygen. You can increase the effectiveness of some radiation treatments by more than 50% using hyperthermia in conjunction with radiation and/or chemotherapy. There are varying degrees of expertise required, but hyperthermia is very...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.